Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 14/20 | 0.46 |
| ▸ | HTR3A | P46098 | 6/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.37 |
| ▸ | HTR3B | O95264 | 1/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23581300 | 1.00 | EZH2 (0.46) | EZH2HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL29741633 | 1.00 | EZH2 (0.46) | EZH2HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL22401173 | 0.85 | EZH2 (0.56) | EZH2 | |
| SCHEMBL22401172 | 0.85 | EZH2 (0.56) | EZH2 | |
| SCHEMBL23606655 | 0.78 | HTR3A (0.44) | HTR3A | |
| SCHEMBL23606586 | 0.78 | EZH2 (0.58) | EZH2 | |
| SCHEMBL29966180 | 0.78 | EZH2 (0.58) | EZH2 | |
| SCHEMBL23672074 | 0.76 | EZH2 (0.60) | EZH2 | |
| SCHEMBL23682259 | 0.76 | EZH2 (0.60) | EZH2 | |
| SCHEMBL29741598 | 0.74 | EZH2 (0.84) | EZH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114787143-A | ZESTE enhancer homolog 2 inhibitors and uses thereof | 四川海思科制药有限公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2021129629-A1 | ZESTE ENHANCER HOMOLOGUE 2 INHIBITOR AND USE THEREOF | 四川海思科制药有限公司 | 2021-07-01 | — | — | WO | disclosed |
| WO-2021129629-A1 | ZESTE ENHANCER HOMOLOGUE 2 INHIBITOR AND USE THEREOF | 四川海思科制药有限公司 | 2021-07-01 | — | — | WO | disclosed |